Loading...
01/10 17:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial performance with significant revenue and net income growth. Despite some concerns such as pipeline risks and gross margin decline, the positive aspects like the successful share buyback program, strong cash position, and optimistic guidance for SUBLOCADE overshadow them. The Q&A further supports a positive outlook with encouraging data on new patient share and strategic focus on SUBLOCADE. Given the market cap, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
Total Net Revenue $307 million, increased 13% year-over-year, driven by SUBLOCADE's growth and fulfillment of OPVEE orders.
SUBLOCADE Net Revenue $191 million, increased 14% year-over-year, primarily due to increased volumes in organized health systems.
Adjusted Operating Profit $97 million, increased 62% year-over-year, benefiting from solid growth in U.S. net revenue and lower overall operating expenses.
Cash Position $344 million at the end of Q3, reflecting strong underlying profitability.
Adjusted Gross Margin 82%, down from the previous year, primarily due to favorable pricing on specific production batches last year and continued cost inflation.
Adjusted SG&A Expenses $133 million, decreased 11% year-over-year, due to the discontinuation of PERSERIS and lower legal and administrative expenses.
R&D Expenses $22 million, increased 22% year-over-year, reflecting the phasing of pipeline advancement activities.
Adjusted Net Income $72 million, increased 47% year-over-year, driven by growth in adjusted operating income.
Net Finance Expense $5 million, compared to net finance income of $2 million in the prior year, primarily due to lower cash and investment balances.
U.S. Patients Treated with SUBLOCADE 166,600, increased 37% year-over-year, with a 4% sequential increase.
Active Dispensing HCPs for SUBLOCADE More than 7,700, representing a 15% increase from the end of fiscal year 2023.
Ex U.S. Sales of SUBLOCADE $13 million, grew 30% year-over-year.
OPVEE Net Revenue $15 million, reflecting two orders as part of a 10-year contract with BARDA.
SUBLOCADE Net Revenue: SUBLOCADE third quarter net revenue of $191 million increased 14% year-over-year.
OPVEE Orders: Booked net revenue for two orders as part of our 10-year contract with BARDA.
Label Updates for SUBLOCADE: Submitted important label updates to the FDA for SUBLOCADE, including rapid induction and alternate sites of injection.
U.S. Patients for SUBLOCADE: U.S. patients and treatment grew 37% year-over-year, reaching 166,600 at the end of the third quarter.
Market Share of New Patients: SUBLOCADE's share of new patients was 72% at the end of the third quarter.
Active Dispensing HCPs: The number of active dispensing HCPs increased to more than 7,700, a 15% increase from the end of fiscal year 2023.
Cost Reduction Actions: Actively pursuing targeted streamlining actions, including cost reductions against the group's expense base.
SG&A Expense Reduction: Adjusted SG&A expenses were $133 million in the quarter, a decrease of 11% versus Q3 of last year.
Pipeline Reprioritization: Discontinued INDV-1000, a preclinical asset targeting alcohol use disorder, narrowing focus to opioid use disorder.
Settlement Agreement: Reached a preliminary agreement for a settlement of $40 million to resolve the last remaining legacy antitrust cases.
Competitive Pressures: SUBLOCADE's growth is being impacted by intensified initial trial and adoption of a competing product, leading to a modest decline in net revenue despite an increase in dispense growth.
Regulatory Issues: The company is awaiting FDA approval for important label updates for SUBLOCADE, which could enhance its market position.
Supply Chain Challenges: There are fluctuations in funding and timing in certain justice system accounts affecting revenue.
Economic Factors: The company is experiencing cost inflation, particularly in wages, raw materials, and services, impacting gross margins.
Litigation Risks: Indivior has reached a preliminary agreement for a $40 million settlement to resolve remaining legacy antitrust cases, with material terms still to be negotiated.
Operational Efficiency: The company is implementing cost reductions and streamlining actions to sharpen strategic focus and protect margins.
SUBLOCADE Revenue Growth: SUBLOCADE third quarter net revenue of $191 million increased 14%, driving a total third quarter net revenue of $307 million, a 13% increase year-over-year.
Patient Growth: U.S. patients and treatment for SUBLOCADE grew 37% year-over-year, reaching 166,600 patients.
Cost Reduction Initiatives: Indivior is pursuing targeted streamlining actions, including cost reductions focused on G&A costs and reprioritizing the R&D pipeline.
Settlement Agreement: Reached a preliminary agreement for a $40 million settlement to resolve remaining legacy antitrust cases.
Pipeline Focus: Narrowing pipeline focus to opioid use disorder with INDV-6001 and INDV-2000, both in Phase 2 studies.
Expansion of Injection Sites: Increased active dispensing HCPs to over 7,700 and added 1,220 alternate injection sites for SUBLOCADE.
2024 Total Net Revenue Guidance: Revised total net revenue guidance of $1.125 billion to $1.165 billion, reflecting a 5% year-over-year growth at midpoint.
SUBLOCADE Revenue Guidance: Guidance for SUBLOCADE set at $725 million to $745 million, representing a 17% year-over-year growth at midpoint.
OPVEE Revenue Expectations: Refined net revenue expectations for OPVEE to approximately $15 million for the year.
Operating Expense Reduction: Expected reduction in total operating expenses by $10 million to $20 million in full year 2025.
Adjusted Operating Income Guidance: Adjusted operating income expected to be between $260 million and $280 million for 2024.
Share Buyback Program: Indivior is more than halfway through the $100 million buyback program announced in late July. Year-to-date, $122 million has been spent on share buybacks through Q3.
The company has raised its financial guidance for 2025, indicating strong performance and growth expectations. The Q&A section reveals effective cost management and strategic focus on SUBLOCADE's growth, with positive indicators such as increased dispense growth and prescriber base. Despite some management evasiveness, the overall sentiment is positive, supported by strong financial metrics and optimistic guidance.
The earnings call presents a mixed picture: modest revenue growth and strong SUBLOCADE performance are offset by execution risks and vague guidance. The Q&A reveals management's strategic focus but lacks specific targets, leading to uncertainty. The stock's market cap suggests modest volatility, aligning with a neutral prediction.
The earnings call indicates strong financial performance with significant revenue and net income growth. Despite some concerns such as pipeline risks and gross margin decline, the positive aspects like the successful share buyback program, strong cash position, and optimistic guidance for SUBLOCADE overshadow them. The Q&A further supports a positive outlook with encouraging data on new patient share and strategic focus on SUBLOCADE. Given the market cap, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
